These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35895443)

  • 1. [Ten-year trends of the characteristics in patients with advanced Parkinson's disease at the time of intestinal gel therapy introduction].
    Szász JA; Szatmári S; Constantin V; Mihály I; Török Á; Frigy A; Metz J; Kelemen K; Szász RM; Forró T; Baróti B; Orbán-Kis K
    Orv Hetil; 2022 Jul; 163(30):1189-1195. PubMed ID: 35895443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Decision-making and duration to accept device-aided therapy in advanced Parkinson’s disease].
    Szász JA; Szatmári S; Constantin V; Mihály I; Rácz A; Frigy A; Nagy E; Kelemen K; Forró T; Almásy E; Orbán-Kis K
    Orv Hetil; 2021 May; 162(21):839-847. PubMed ID: 34023813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characteristics of levodopa treatment in advanced Parkinson's disease in the experiences of the neurology clinics of Târgu Mureș, Romania].
    Szász JA; Szatmári S; Constantin V; Mihály I; Rácz A; Domokos LC; Vajda T; Orbán-Kis K
    Orv Hetil; 2019 Apr; 160(17):662-669. PubMed ID: 31010306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-Carbidopa Intestinal Gel Injection for Patient with Severe Parkinson's Disease Followed by Total Hip Arthroplasty: A Case Report and Literature Review.
    Imamura A; Kuroyanagi G; Usami T; Sato T; Horiba M; Sakai H; Takahashi A; Ueki Y; Matsukawa N; Murakami H
    Orthop Surg; 2023 Nov; 15(11):2993-2999. PubMed ID: 37712322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
    Marano M; Naranian T; di Biase L; Di Santo A; Poon YY; Arca R; Cossu G; Marano P; Di Lazzaro V; Fasano A
    Parkinsonism Relat Disord; 2019 Dec; 69():140-146. PubMed ID: 31759188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
    Meloni M; Solla P; Mascia MM; Marrosu F; Cannas A
    Parkinsonism Relat Disord; 2017 Apr; 37():92-96. PubMed ID: 28063683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
    Timofeeva AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
    Fernandez HH; Boyd JT; Fung VSC; Lew MF; Rodriguez RL; Slevin JT; Standaert DG; Zadikoff C; Vanagunas AD; Chatamra K; Eaton S; Facheris MF; Hall C; Robieson WZ; Benesh J; Espay AJ
    Mov Disord; 2018 Jul; 33(6):928-936. PubMed ID: 29570853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
    Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
    Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
    Chaudhuri KR; Pickard AS; Alobaidi A; Jalundhwala YJ; Kandukuri PL; Bao Y; Sus J; Jones G; Ridley C; Oddsdottir J; Najle-Rahim S; Madin-Warburton M; Xu W; Schrag A
    Pharmacoeconomics; 2022 May; 40(5):559-574. PubMed ID: 35307793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson's disease: is it an improvement on other delivery?
    Doggrell SA
    Expert Opin Drug Deliv; 2023; 20(9):1189-1199. PubMed ID: 37634938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland.
    Weiss D; Ebersbach G; Möller JC; Schwarz J; Arlt C; Fritz B; Sensken SC; Eggert K
    Parkinsonism Relat Disord; 2022 Oct; 103():85-91. PubMed ID: 36087571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
    Fabbri M; Pongmala C; Artusi CA; Romagnolo A; Rizzone MG; Zibetti M; Lopiano L
    Acta Neurol Scand; 2019 Aug; 140(2):157-161. PubMed ID: 31025312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.